<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800746</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1160000</org_study_id>
    <nct_id>NCT02800746</nct_id>
  </id_info>
  <brief_title>Intravenous Iron Pre-treatment in Prognathic Surgery</brief_title>
  <official_title>Preoperative Intravenous Iron Supplementation on Postoperative Hematocrit and Intraoperative Transfusion Amount in Prognathic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to determine the impact of preoperative IV-iron (ferric
      carboxy maltose) supplementation on postoperative hematocrit values and allogenic blood
      transfusion amount in patients undergoing elective prognathic surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum-Hematocrit</measure>
    <time_frame>Postoperative 2 hour</time_frame>
    <description>intergroup-difference immediately after surgery, %</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum-Ferritin level</measure>
    <time_frame>Postoperative 2 hour</time_frame>
    <description>intergroup-difference in postoperative hematocrit level, %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of serum-Ferritin level</measure>
    <time_frame>Postoperative 2 hour</time_frame>
    <description>Intragroup-difference in the s-ferritin before and immediately after surgery, mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion amount</measure>
    <time_frame>Postoperative 2 hour</time_frame>
    <description>intergroup-difference in the amount of packed RBC transfused during surgery, unit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Prognathic Surgery</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric carboxymaltose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline 100 ml is intravenously administered on 7-10 day before surgery</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with prognathism in undergoing elective prognathic surgery

          -  Patients provided a written informed consent.

          -  Patients with s-ferritin &lt; 300 mg/dl (male) or 200 mg/dl (female)

          -  Patients with preoperative Hematocrit &gt; 39% (male) and &gt; 36% 9female)serum hemoglobin
             &gt;13 g/dL (male) and &gt;12 g/dL (female)

        Exclusion Criteria:

          -  Patients with history of anaphylaxis, iron overload, active infection.

          -  Patients with endocrine disease

          -  Patients received or receiving intraoperative and preoperative blood salvaged,
             allogenic blood transfusion, anti-fibrinolytic agents or recombinant human
             erythropoietin, or undergoing acute normovolemic hemodilution.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tae-Yop Kim, MD, PhD</last_name>
    <phone>82-2-2030-5445</phone>
    <email>taeyop@gmail.com</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2016</study_first_submitted>
  <study_first_submitted_qc>June 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Yop Kim, MD PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Prognathic surgery</keyword>
  <keyword>intravenous iron</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

